Highview Capital Management LLC DE Cuts Stock Position in Edwards Lifesciences Corporation $EW

Highview Capital Management LLC DE trimmed its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 65.4% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,775 shares of the medical research company’s stock after selling 5,250 shares during the period. Highview Capital Management LLC DE’s holdings in Edwards Lifesciences were worth $217,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Edwards Lifesciences by 1.2% during the 2nd quarter. Vanguard Group Inc. now owns 69,997,629 shares of the medical research company’s stock worth $5,474,515,000 after purchasing an additional 798,801 shares during the last quarter. Intrust Bank NA lifted its position in shares of Edwards Lifesciences by 16.9% in the second quarter. Intrust Bank NA now owns 13,755 shares of the medical research company’s stock valued at $1,076,000 after acquiring an additional 1,991 shares in the last quarter. Citigroup Inc. lifted its position in shares of Edwards Lifesciences by 30.3% in the second quarter. Citigroup Inc. now owns 1,385,415 shares of the medical research company’s stock valued at $108,353,000 after acquiring an additional 321,986 shares in the last quarter. Midwest Professional Planners LTD. boosted its stake in shares of Edwards Lifesciences by 1.1% in the second quarter. Midwest Professional Planners LTD. now owns 37,451 shares of the medical research company’s stock worth $2,929,000 after acquiring an additional 413 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH increased its position in shares of Edwards Lifesciences by 6.4% during the second quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 1,484,222 shares of the medical research company’s stock worth $116,081,000 after purchasing an additional 89,122 shares in the last quarter. Institutional investors and hedge funds own 79.46% of the company’s stock.

Edwards Lifesciences Trading Down 0.7%

Shares of Edwards Lifesciences stock opened at $84.13 on Wednesday. The stock has a 50 day moving average of $78.37 and a 200 day moving average of $77.88. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.87 and a current ratio of 4.68. The firm has a market capitalization of $48.82 billion, a price-to-earnings ratio of 12.11, a PEG ratio of 3.97 and a beta of 1.03. Edwards Lifesciences Corporation has a fifty-two week low of $65.94 and a fifty-two week high of $87.21.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The company’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. As a group, research analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Insider Activity

In other news, CFO Scott B. Ullem sold 13,000 shares of the company’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $83.08, for a total value of $1,080,040.00. Following the transaction, the chief financial officer directly owned 39,898 shares in the company, valued at approximately $3,314,725.84. This represents a 24.58% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 1,020 shares of the stock in a transaction that occurred on Monday, November 10th. The stock was sold at an average price of $82.55, for a total transaction of $84,201.00. Following the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,816,265.10. The trade was a 4.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.29% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on EW. Citigroup raised their price objective on Edwards Lifesciences from $95.00 to $96.00 and gave the company a “buy” rating in a report on Friday, October 31st. Raymond James Financial upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and set a $96.00 target price for the company in a research report on Monday, November 3rd. Truist Financial boosted their price target on shares of Edwards Lifesciences from $87.00 to $90.00 and gave the stock a “hold” rating in a research report on Monday, November 3rd. Daiwa America raised shares of Edwards Lifesciences from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 29th. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $90.00 target price on shares of Edwards Lifesciences in a research note on Monday, November 3rd. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $91.39.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.